First Regulatory Approval in Europe for DMX-200 FSGS Study
Filed with ASX · · 3 pages · English
Story so far
Earlier from Dimerix
- Patients Dosed in DMX-200 COVID-19 Phase 3 Study in India
- Ethics Approval in Australia for Phase 3 COVID-19 Study
- DSMB Recommends Continuation of Ph3 COVID-19 Study in Europe
- Pause in Trading
- First Approvals Received for Start of Phase 3 FSGS Trial
Later from Dimerix
- Half-Year Financial Report & Appendix 4D - 31 December 2021
- DSMB Change to REMAP-CAP COVID-19 Study
- Dimerix Receives A$3.7M R&D Tax Incentive Rebate
- FDA IND Approval for Phase 3 Study of DMX-200 in FSGS
- Dimerix presentation at Bioshares Biotech Summit
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix